Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 3:00 am
Author: Getaka|Social: XLinkedIn

Gufic BioSciences Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹353.63Undervalued by 22.36%vs CMP ₹289.00

P/E (57.3) × ROE (12.3%) × BV (₹62.70) × DY (0.03%)

₹126.44Overvalued by 56.25%vs CMP ₹289.00
MoS: -128.6% (Negative)Confidence: 63/100 (Moderate)Models: 1 Fair, 8 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹308.9022%Fair (+6.9%)
Graham NumberEarnings₹84.2416%Over (-70.9%)
Earnings PowerEarnings₹29.1613%Over (-89.9%)
DCFCash Flow₹13.3713%Over (-95.4%)
Net Asset ValueAssets₹62.797%Over (-78.3%)
EV/EBITDAEnterprise₹151.249%Over (-47.7%)
Earnings YieldEarnings₹50.307%Over (-82.6%)
ROCE CapitalReturns₹150.949%Over (-47.8%)
Revenue MultipleRevenue₹122.795%Over (-57.5%)
Consensus (9 models)₹126.44100%Overvalued
Key Drivers: Wide model spread (₹13–₹309) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: -12.6%

*Investments are subject to market risks

Investment Snapshot

57
Gufic BioSciences Ltd scores 57/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health73/100 · Strong
ROCE 13.2% GoodROE 12.3% GoodD/E 0.59 ModerateInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent
Smart Money60/100 · Moderate
FII holding up 0.13% (6mo) Slight increasePromoter holding at 72.5% Stable
Earnings Quality50/100 · Moderate
OPM stable around 18% Steady
Quarterly Momentum50/100 · Moderate
Revenue (4Q): +8% YoY GrowingProfit (4Q): -36% YoY Declining
Industry Rank45/100 · Moderate
P/E 57.3 vs industry 53.8 In-lineROCE 13.2% vs industry 16.4% Average3Y sales CAGR: 2% Slow

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 3:00 am

Market Cap 2,895 Cr.
Current Price 289
Intrinsic Value₹126.44
High / Low 409/268
Stock P/E57.3
Book Value 62.7
Dividend Yield0.03 %
ROCE13.2 %
ROE12.3 %
Face Value 1.00
PEG Ratio-4.53

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Gufic BioSciences Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Gufic BioSciences Ltd 2,895 Cr. 289 409/26857.3 62.70.03 %13.2 %12.3 % 1.00
Advanced Enzyme Technologies Ltd 2,981 Cr. 266 367/25220.7 1331.95 %13.1 %9.54 % 2.00
Gujarat Themis Biosyn Ltd 2,692 Cr. 247 479/22256.3 24.30.27 %27.3 %21.7 % 1.00
RPG Life Sciences Ltd 3,105 Cr. 1,878 2,725/1,73129.6 3351.07 %32.8 %25.5 % 8.00
Orchid Pharma Ltd 2,634 Cr. 519 899/471101 2510.00 %8.07 %8.21 % 10.0
Industry Average19,815.15 Cr1,053.8453.84201.200.39%16.35%15.16%6.10

All Competitor Stocks of Gufic BioSciences Ltd

Quarterly Result

MetricSep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Sales 175177173195215202195203204208205227230
Expenses 142143141160176165161167166174178195195
Operating Profit 33343235393634363934273236
OPM % 19%19%19%18%18%18%18%18%19%16%13%14%16%
Other Income 1111001102012
Interest 22344345558910
Depreciation 5664444445888
Profit before tax 27272428313027282926111621
Tax % 26%25%24%26%25%25%26%26%26%26%26%26%27%
Net Profit 2020182123222021221981215
EPS in Rs 2.082.101.872.132.392.222.002.082.171.930.791.201.49

Last Updated: January 1, 2026, 1:46 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 24, 2026, 7:16 am

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 121148201245306351379488779691807820893
Expenses 109134181222267305327404631556657683762
Operating Profit 1214202339465284148135150136131
OPM % 10%10%10%9%13%13%14%17%19%20%19%17%15%
Other Income 1111446433-044
Interest 4466910141458172536
Depreciation 24444514161922172131
Profit before tax 671014303530581271071169469
Tax % 32%36%29%37%45%38%25%23%24%25%26%26%
Net Profit 4479162223449680867051
EPS in Rs 0.550.540.951.172.132.822.925.689.898.228.596.975.03
Dividend Payout % 9%9%5%4%2%2%2%2%1%1%1%1%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)0.00%75.00%28.57%77.78%37.50%4.55%91.30%118.18%-16.67%7.50%-18.60%
Change in YoY Net Profit Growth (%)0.00%75.00%-46.43%49.21%-40.28%-32.95%86.76%26.88%-134.85%24.17%-26.10%

Gufic BioSciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:19%
5 Years:17%
3 Years:2%
TTM:4%
Compounded Profit Growth
10 Years:33%
5 Years:25%
3 Years:-10%
TTM:-29%
Stock Price CAGR
10 Years:30%
5 Years:35%
3 Years:16%
1 Year:-7%
Return on Equity
10 Years:23%
5 Years:22%
3 Years:18%
Last Year:12%

Last Updated: September 5, 2025, 5:30 am

Balance Sheet

Last Updated: December 4, 2025, 1:19 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 88888810101010101010
Reserves 181926304668120164259338523591619
Borrowings 3333435780981266264334333336369
Other Liabilities 52677584104106152157188179227232271
Total Liabilities 1111271521782382804083925218611,0931,1701,268
Fixed Assets 30252222232483100115160159506495
CWIP 00002103113411703072224
Investments 0000000001233
Other Assets 81102130156213245294279365531625639747
Total Assets 1111271521782382804083925218611,0931,1701,268

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 1111-4-4-554787106-27-7123
Cash from Investing Activity + -3-2-1-5-9-13-43-7-95-191-102-72
Cash from Financing Activity + -7-557148-4-79-623482-37
Net Cash Flow 14-0-11-002517-2714
Free Cash Flow 89-5-8-13-877519-214-11652
CFO/OP 103%92%-8%2%30%33%110%115%94%1%13%107%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-21.00-19.00-23.00-34.00-41.00-52.00-74.0022.0084.00-199.00-183.00-200.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 858210278971071039371109149140
Inventory Days 144165180190238190249138102202188211
Days Payable 176223188132192157238162125143156155
Cash Conversion Cycle 5425941361431411146948167181197
Working Capital Days 20418142640176350689793
ROCE %17%18%24%24%33%30%21%29%46%23%17%13%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 75.00%75.00%75.00%72.51%72.51%72.51%72.51%72.51%72.51%72.51%72.50%72.50%
FIIs 0.72%0.70%0.72%0.47%0.12%0.23%0.23%0.30%0.31%0.32%0.33%0.44%
DIIs 1.16%1.16%1.63%1.72%2.20%2.38%2.51%2.99%3.39%3.38%3.66%3.74%
Public 23.12%23.12%22.64%25.29%25.17%24.89%24.75%24.20%23.79%23.81%23.51%23.30%
No. of Shareholders 38,90238,62436,55734,42434,69532,25032,82533,29931,84431,87631,42030,362

Shareholding Pattern Chart

No. of Shareholders

Gufic BioSciences Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
ICICI Prudential Multicap Fund 1,480,998 0.29 45.5N/AN/AN/A
SBI Healthcare Opportunities Fund 1,000,000 0.8 30.731,000,0002025-04-22 17:25:340%
ICICI Prudential Smallcap Fund 446,517 0.17 13.72441,2932025-12-15 09:10:001.18%
Bank of India Small Cap Fund 353,689 0.59 10.87348,4632026-01-25 06:13:371.5%
ICICI Prudential ELSS Tax Saver Fund 74,008 0.02 2.27N/AN/AN/A
ICICI Prudential Bharat Consumption Fund 58,263 0.06 1.7939,1972026-02-23 03:46:1748.64%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24
FaceValue 1.001.00
Basic EPS (Rs.) 6.958.74
Diluted EPS (Rs.) 6.958.74
Cash EPS (Rs.) 9.0510.29
Book Value[Excl.RevalReserv]/Share (Rs.) 59.9453.11
Book Value[Incl.RevalReserv]/Share (Rs.) 59.9453.11
Revenue From Operations / Share (Rs.) 81.7580.44
PBDIT / Share (Rs.) 13.9314.76
PBIT / Share (Rs.) 11.8313.07
PBT / Share (Rs.) 9.3911.54
Net Profit / Share (Rs.) 6.958.59
NP After MI And SOA / Share (Rs.) 6.958.59
PBDIT Margin (%) 17.0418.35
PBIT Margin (%) 14.4716.24
PBT Margin (%) 11.4814.33
Net Profit Margin (%) 8.4910.67
NP After MI And SOA Margin (%) 8.4910.67
Return on Networth / Equity (%) 11.5816.17
Return on Capital Employeed (%) 15.1718.18
Return On Assets (%) 5.957.88
Long Term Debt / Equity (X) 0.210.28
Total Debt / Equity (X) 0.510.59
Asset Turnover Ratio (%) 0.720.00
Current Ratio (X) 1.611.61
Quick Ratio (X) 1.051.08
Inventory Turnover Ratio (X) 3.930.00
Dividend Payout Ratio (NP) (%) 1.431.12
Dividend Payout Ratio (CP) (%) 1.100.93
Earning Retention Ratio (%) 98.5798.88
Cash Earning Retention Ratio (%) 98.9099.07
Interest Coverage Ratio (X) 5.709.64
Interest Coverage Ratio (Post Tax) (X) 3.846.61
Enterprise Value (Cr.) 3655.213142.92
EV / Net Operating Revenue (X) 4.463.90
EV / EBITDA (X) 26.1621.23
MarketCap / Net Operating Revenue (X) 4.123.52
Retention Ratios (%) 98.5698.87
Price / BV (X) 5.615.33
Price / Net Operating Revenue (X) 4.123.52
EarningsYield 0.020.03

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Gufic BioSciences Ltd. is a Public Limited Listed company incorporated on 23/07/1984 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24100MH1984PLC033519 and registration number is 033519. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 819.81 Cr. and Equity Capital is Rs. 10.03 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
Pharmaceuticals37, First Floor, Kamala Bhavan II, Mumbai Maharashtra 400069Contact not found
Management
NamePosition Held
Mr. Jayesh P ChoksiChairman & Managing Director
Mr. Pranav J ChoksiWholeTime Director & CEO
Mr. Pankaj J GandhiWhole Time Director
Dr. Anu S AuoraIndependent Director
Mr. Kamal K SethIndependent Director
Mr. Akshya Kumar MahapatraIndependent Director

FAQ

What is the intrinsic value of Gufic BioSciences Ltd and is it undervalued?

As of 13 April 2026, Gufic BioSciences Ltd's intrinsic value is ₹126.44, which is 56.25% lower than the current market price of ₹289.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (12.3 %), book value (₹62.7), dividend yield (0.03 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Gufic BioSciences Ltd?

Gufic BioSciences Ltd is trading at ₹289.00 as of 13 April 2026, with a FY2026-2027 high of ₹409 and low of ₹268. The stock is currently near its 52-week low. Market cap stands at ₹2,895 Cr..

How does Gufic BioSciences Ltd's P/E ratio compare to its industry?

Gufic BioSciences Ltd has a P/E ratio of 57.3, which is above the industry average of 53.84. The premium over industry average may reflect growth expectations or speculative interest.

Is Gufic BioSciences Ltd financially healthy?

Key indicators for Gufic BioSciences Ltd: ROCE of 13.2 % is moderate. Dividend yield is 0.03 %.

Is Gufic BioSciences Ltd profitable and how is the profit trend?

Gufic BioSciences Ltd reported a net profit of ₹70 Cr in Mar 2025 on revenue of ₹820 Cr. Compared to ₹96 Cr in Mar 2022, the net profit shows a declining trend.

Does Gufic BioSciences Ltd pay dividends?

Gufic BioSciences Ltd has a dividend yield of 0.03 % at the current price of ₹289.00. The company pays dividends, though the yield is modest.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Gufic BioSciences Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports